公开(公告)号：US20130157959A1

公开(公告)日：2013-06-20

申请号：US13641910

申请日：2011-04-21

申请人： Sungkwan An ,  Jin Hyuk Jung ,  Jae Ho Lee ,  Seunghee Bae

发明人： Sungkwan An ,  Jin Hyuk Jung ,  Jae Ho Lee ,  Seunghee Bae

IPC分类号： A61K38/17

CPC分类号： A61K38/17 ,  A61K38/53 ,  C07K16/18

摘要： The present invention relates to a new use of Hades as a tumor suppressor target, more particularly to a composition for suppressing tumor comprising an expression or action inhibitor of Hades protein having an amino acid sequence of SEQ ID NO: 2 as an effective ingredient. The present inventors have found that the overexpressed Hades protein interacts with p53 to inhibit the exonuclear mechanism of p53 and the knowdown of Hades induces increase in the expression of p53, demonstrating that Hades is a negative regulator to p53. Therefore, it would be understood that the inhibition of Hades overexpressed in tumor cells contributes to tumor-supressive effects of p53. The drug candidates capable of modulating the expression of the Hades protein, inhibiting the actions of the Hades protein or inhibiting interecation between Hades and p53 are considered a promising anticancer drug.

摘要翻译： 本发明涉及Hades作为肿瘤抑制靶的新用途，更具体地，涉及具有SEQ ID NO：2的氨基酸序列的Hades蛋白的表达或抑制剂作为有效成分的抑制肿瘤的组合物。 本发明人已经发现，过表达的Hades蛋白与p53相互作用以抑制p53的外核机制，并且Hades的知识诱导p53表达增加，表明Hades是p53的负调节因子。 因此，应当理解，在肿瘤细胞中过表达的Hades的抑制有助于p53的肿瘤抑制作用。 能够调节Hades蛋白表达，抑制Hades蛋白的作用或抑制Hades和p53之间的相互作用的候选药物被认为是有希望的抗癌药物。